Head of the department- hematologist of the Department of Hematology and Chemotherapy of Paraproteinemic Hemoblastosis with Bone Marrow and Hematopoietic Stem Cell Transplantation Unit
Candidate of Medical Sciences, hematologist of the first qualification category, senior researcher of the Division of Chemotherapy of Paraproteinemic Hemoblastosis
Maxim Soloviev graduated with honors from the Krasnoyarsk State Medical University named after Prof. V.F. Voyno-Yasenetsky and was awarded the qualification of a doctor in the specialty "General Medicine" (2012).
He completed a clinical internship at the Department of Therapy of the Institute of Postgraduate Education of the Krasnoyarsk State Medical University named after Prof. V.F. Voyno-Yasenetsky and was awarded the qualification of a doctor in the specialty "Therapy" (2012 - 2013).
He then graduated from residency at the NMRC for Hematology, receiving a certificate of a hematology specialist (2015). He studied in full-time postgraduate studies in the specialty "hematology and blood transfusion" at the Department of Intensive High-dose Chemotherapy for Paraproteinemic Hemoblastosis (2015 - 2018).
He defended his dissertation for the degree of Candidate of Medical Sciences on the topic: "Detection and monitoring of minimal residual disease after transplantation of autologous hematopoietic stem cells in patients with multiple myeloma" (2018).
Soloviev is learned in the modern methods of diagnosis and therapy of hematological patients. He participates in the development and implementation of the latest treatment methods in the clinic including intensive induction and high-dose consolidation with subsequent transplantation of autologous and allogeneic hematopoietic stem cells.
He supervises and advises patients with plasma cell tumors in the clinical departments of the NMRC for Hematology, in various medical organizations in Moscow and other cities of the Russian Federation. He actively participates in telemedicine consultations of complex cases of differential diagnosis and treatment.
Maxim Soloviev’s scientific and clinical activity is devoted to the study of various aspects of multiple myeloma and other paraproteinemic hemoblastosis. He is the coordinator of a multicenter prospective observational registration study to assess the epidemiological characteristics and clinical features of multiple myeloma in Russia. More than 44 hematology centers from 40 regions of Russia participated in the study.
He takes an active part in international clinical studies devoted to the study of the effectiveness of the therapeutic effects of innovative drugs in the refractory-relapse course of multiple myeloma. Throughout the years, the department has conducted clinical trials of 6 drugs for the treatment of relapses of multiple myeloma.
Soloviev pays great attention to scientific work. The focus of his research is devoted to the study of the biology and pathogenesis of multiple myeloma and other paraproteinemic hemoblastosis – the assessment of risk factors at the genetic and cytogenetic levels, the determination of the role of minimal residual disease at different stages of program therapy, the creation of a differentiated strategy of supportive treatment of patients after autologous stem cell transplantation taking into account the residual tumor, and the study of the pathogenetic foundations of the formation of extramedullary forms of the disease.
He regularly presents the results of scientific and clinical activities in the form of scientific publications and poster/oral reports at various international and domestic conferences.
Soloviev is a co-author of Russian Clinical Guidelines for the diagnosis and treatment of multiple myeloma. He participates in the preparation of standards for the provision of medical care in the profile "hematology", revises the lists of high- tech medical care, and is an expert of the Ministry of Health of the Russian Federation for the approval of annual applications of drugs from the list of the 14 high-cost nosologies.
Maxim Soloviev consistently improves upon his professional knowledge and skills, carrying out clinical activities in three specialties: "hematology" (2020), "therapy" (2018), "organization of public health and healthcare" (2021).
